Literature DB >> 28623538

Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.

L Keith Scott1, Robert Toner2.   

Abstract

Cystic fibrosis is a complex genetic disease hallmarked by repetitive infectious exacerbations that leads to destruction of airway architecture, acute on chronic inflammatory changes, and deterioration in lung function. Predicting an exacerbation may help preempt some of these changes by the initiation of swift antibiotic and anti-inflammatory therapy. A search for biomarkers that could predict exacerbations or help guide duration of antibiotic therapy is being aggressively sought. In this review, we discuss the most recent and promising biomarkers that hopefully will assist in the future management of the CF patient.

Entities:  

Keywords:  Biomarkers; Cystic fibrosis; Cystic fibrosis pulmonary exacerbation

Mesh:

Substances:

Year:  2017        PMID: 28623538     DOI: 10.1007/s00408-017-0024-3

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  33 in total

1.  Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis.

Authors:  Maria Entezari; Daniel J Weiss; Ravikumar Sitapara; Laurie Whittaker; Matthew J Wargo; JianHua Li; Haichao Wang; Huan Yang; Lokesh Sharma; Binh D Phan; Mohammad Javdan; Sangeeta S Chavan; Edmund J Miller; Kevin J Tracey; Lin L Mantell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 2.  Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Jessica E Pittman; Garry Cutting; Stephanie D Davis; Thomas Ferkol; Richard Boucher
Journal:  Ann Am Thorac Soc       Date:  2014-04

3.  Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Patrick D Schloss; Joseph F Petrosino; Susan Murray; Vincent B Young; Jun Z Li; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2013-06

Review 4.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

5.  Nasal high-mobility group box-1 protein in children with allergic rhinitis.

Authors:  C Salpietro; C Cuppari; L Grasso; M A Tosca; M Miraglia Del Giudice; M La Rosa; G L Marseglia; A Salpietro; G Ciprandi
Journal:  Int Arch Allergy Immunol       Date:  2013-01-22       Impact factor: 2.749

Review 6.  Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations.

Authors:  Alborz Hakimi Shoki; Nicole Mayer-Hamblett; Pearce G Wilcox; Don D Sin; Bradley S Quon
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

7.  A microRNA network regulates expression and biosynthesis of wild-type and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator.

Authors:  Shyam Ramachandran; Philip H Karp; Peng Jiang; Lynda S Ostedgaard; Amy E Walz; John T Fisher; Shaf Keshavjee; Kim A Lennox; Ashley M Jacobi; Scott D Rose; Mark A Behlke; Michael J Welsh; Yi Xing; Paul B McCray
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-01       Impact factor: 11.205

Review 8.  The Social Life of Aeromonas through Biofilm and Quorum Sensing Systems.

Authors:  Emilie Talagrand-Reboul; Estelle Jumas-Bilak; Brigitte Lamy
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

9.  C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.

Authors:  Elias Matouk; Dao Nguyen; Andrea Benedetti; Joanie Bernier; James Gruber; Jennifer Landry; Simon Rousseau; Heather G Ahlgren; Larry C Lands; Gabriella Wojewodka; Danuta Radzioch
Journal:  J Pulm Respir Med       Date:  2016-10-14

10.  Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis.

Authors:  Bradley S Quon; David A Ngan; Pearce G Wilcox; S F Paul Man; Don D Sin
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

View more
  2 in total

Review 1.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 2.  Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.

Authors:  Kate Skolnik; Bradley S Quon
Journal:  F1000Res       Date:  2018-05-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.